CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Purdue Pharma L.P. v. Impax Laboratories, Inc.

1:13-cv-03188

Overview

Case Number 1:13-cv-03188
Filing Date 2013-05-10
Status Terminated
Termination Date 2013-12-06
Court District Court, S.D. New York (nysd)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Impax Laboratories, Inc. Operating Company

Represented By

1 Attorneys Listed

Counter Defendant

The P.F. Laboratories, Inc. Operating Company

Represented By

2 Attorneys Listed

Purdue Pharmaceuticals L.P. NPE (University / Research)

Represented By

2 Attorneys Listed

Purdue Pharma L.P. NPE (University / Research)

Represented By

2 Attorneys Listed

Court & Judges

Court

District Court, S.D. New York (nysd)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 22 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (22): πŸ‡©πŸ‡ͺ Germany πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8114383
Abuse-proofed dosage form
Filed: 2003-11-20
Issued: 2012-02-14
Expired (Term Ended) +325d PTA
Expires: 2024-10-10

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+325 days) / Cellect Scrutiny β€” Over 325 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

3

Dispositive

0

Granted

0

Denied

0

Pending / Review

2

Motions by Category

Claim Construction / Markman Filing 3

Key Dispositive Motions & Rulings

Claim Construction / Markman Filing Pending
ORDER:The Parties, by agreement, will exchange initial disclosures pursuant to Rule 26(a)(1) of the F.R.C.P. on the date indicated below. Except as specified by...
Entry #13 • 2013-09-20 Document →
Claim Construction / Markman Filing Pending / Under Review
ORDER:The Parties, by agreement, will exchange initial disclosures pursuant to Rule 26(a)(1) of the F.R.C.P. on the date indicated below. Except as specified by...
Entry #13 • 2013-09-20 Document →
Claim Construction / Markman Filing Pending / Under Review
ORDER. It is hereby ordered that the parties shall submit to the Court by August 16, 2013, a proposed schedule for these actions, including a joint discovery pl...
Entry #8 • 2013-07-30 Document →

Docket Entries

(15 total)
Pleading / Complaint

COMPLAINT against Impax Laboratories, Inc. (Filing Fee $ 350.00, Receipt Number 465401067255)Document filed by The P.F. Laboratories, Inc., Purdue Pharma L.P., Purdue Pharmaceuticals L.P.(mqu) (mqu). (Entered: 05/13/2013)

Entry #1 • 2013-05-10
1
Court Order

STANDING ORDER IN RE PILOT PROJECT REGARDING CASE MANAGEMENT TECHNIQUES FOR COMPLEX CIVIL CASES IN THE SOUTHERN DISTRICT OF NEW YORK (See M-10-468 Order filed November 1, 2011). This case is hereby designated for inclusion in the Pilot Project Regarding Case Management Techniques for Complex Civil Cases in the Southern District of New York (the Pilot Project), unless the judge to whom this case is assigned determines otherwise. This case is designated for inclusion in the Pilot Project because it is a class action, an MDL action, or is in one of the following Nature of Suit categories: 160, 245, 315, 355, 365, 385, 410, 830, 840, 850, 893, or 950. The presiding judge in a case that does not otherwise qualify for inclusion in the Pilot Project may nevertheless designate the case for inclusion in the Pilot Project by issuing an order directing that the case be included in the Pilot Project. The description of the Pilot Project, including procedures to be followed, is attached to this Order. (Signed by Judge Loretta A. Preska on 10/31/2011) (mqu) (Entered: 05/13/2013)

Entry #2 • 2013-05-10
1

NOTICE OF CASE ASSIGNMENT to Judge Sidney H. Stein. Judge Unassigned is no longer assigned to the case. (pgu) (Entered: 05/17/2013)

Entry #3 • 2013-05-17
1

RULE 7.1 CORPORATE DISCLOSURE STATEMENT. Identifying Other Affiliate Purdue Pharma L.P. for Purdue Pharmaceuticals L.P.; Corporate Parent Pharmaceutical Research Associates, Inc. for The P.F. Laboratories, Inc.; Other Affiliate Purdue Holdings L.P. for Purdue Pharma L.P.. Document filed by Purdue Pharma L.P., Purdue Pharmaceuticals L.P., The P.F. Laboratories, Inc..(Hendler, Pablo) (Entered: 05/17/2013)

Entry #4 • 2013-05-17
1

RULE 7.1 CORPORATE DISCLOSURE STATEMENT. No Corporate Parent. Document filed by Impax Laboratories, Inc..(Lamut, Anna) (Entered: 06/07/2013)

Entry #5 • 2013-06-07
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc